Calidi Biotherapeutics (CLDI) Other Non-Current Assets (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Other Non-Current Assets of $138000.0 for Q4 2025, down 9.21% year-over-year from $152000.0 in Q4 2024, and down 31.0% quarter-over-quarter from $200000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $138000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Assets fell 9.21% year-over-year to $138000.0; the TTM figure through Dec 2025 stood at $138000.0 (down 9.21% YoY), while the FY2025 annual figure was $138000.0, down 9.21% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $138000.0, down from $200000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $725000.0 in Q4 2022, with the low at $77033.0 in Q2 2022.
- The 5-year median for Other Non-Current Assets is $200000.0 (2023), against an average of $231568.9.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets soared 158.06% in 2022, then slumped 59.25% in 2024.
- Calidi Biotherapeutics' Other Non-Current Assets stood at $280944.0 in 2021, then jumped by 158.06% to $725000.0 in 2022, then plunged by 48.55% to $373000.0 in 2023, then plunged by 59.25% to $152000.0 in 2024, then dropped by 9.21% to $138000.0 in 2025.
- Business Quant data shows CLDI's Other Non-Current Assets at $138000.0 in Q4 2025, $200000.0 in Q3 2025, and $100000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Dec 31, 2025 | 138,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 152,000.00 |
| Sep 30, 2024 | 217,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 200,000.00 |
| Dec 31, 2023 | 373,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Dec 31, 2022 | 725,000.00 |
| Jun 30, 2022 | 77,033.00 |
| Mar 31, 2022 | 178,988.00 |
| Dec 31, 2021 | 280,944.00 |